Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer. Export

@article{citeulike:6083180, abstract = {BACKGROUND: Breast cancer concern is a major reason for the recent marked reduction in use of postmenopausal hormone therapy, although equally effective means of controlling menopausal symptoms are lacking. Single nucleotide polymorphisms (SNP) in the fibroblast growth factor receptor 2 (FGFR2) gene are substantially associated with postmenopausal breast cancer risk and could influence hormone therapy effects. Participants and METHODS: We interrogated eight SNPs in intron 2 of the FGFR2 gene for 2,166 invasive breast cancer cases from the Women's Health Initiative clinical trial and one-to-one matched controls to confirm an association with breast cancer risk. We used case-only analyses to examine the dependence of estrogen plus progestin and estrogen-alone odds ratios on SNP genotype. RESULTS: Seven FGFR2 SNPs, including six in a single linkage disequilibrium region, were found to associate strongly (P < 10(-7)) with breast cancer risk. SNP rs3750817 (minor allele T with frequency 0.39) had an estimated per-minor-allele odds ratio of 0.78, and was not in such strong linkage disequilibrium with the other SNPs. The genotype of this SNP related significantly (P < 0.05) to hormone therapy odds ratios. For estrogen plus progestin, the odds ratios (95\% confidence intervals) at 0, 1, and 2 minor SNP alleles were 1.52 (1.14-2.02), 1.33 (1.01-1.75), and 0.69 (0.41-1.17), whereas the corresponding values for estrogen alone were 0.74 (0.51-1.09), 0.99 (0.68-1.44), and 0.34 (0.15-0.76). CONCLUSIONS: Postmenopausal women having TT genotype for SNP rs3750817 have a reduced breast cancer risk and seem to experience comparatively favorable effects of postmenopausal hormone therapy. (Cancer Epidemiol Biomarkers Prev 2009;18(11):3079-85).}, author = {Prentice, Ross L. and Huang, Ying and Hinds, David A. and Peters, Ulrike and Pettinger, Mary and Cox, David R. and Beilharz, Erica and Chlebowski, Rowan T. and Rossouw, Jacques E. and Caan, Bette and Ballinger, Dennis G.}, citeulike-article-id = {6083180}, citeulike-linkout-0 = {http://dx.doi.org/10.1158/1055-9965.EPI-09-0611}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19861516}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19861516}, day = {27}, doi = {10.1158/1055-9965.EPI-09-0611}, issn = {1538-7755}, journal = {Cancer epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, keywords = {breast, cancer, fgfr2, polymorphism}, month = {October}, posted-at = {2009-11-07 17:59:33}, priority = {2}, title = {Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer.}, url = {http://dx.doi.org/10.1158/1055-9965.EPI-09-0611}, year = {2009} }

TY - JOUR ID - citeulike:6083180 L3 - citeulike-article-id:6083180 N2 - BACKGROUND: Breast cancer concern is a major reason for the recent marked reduction in use of postmenopausal hormone therapy, although equally effective means of controlling menopausal symptoms are lacking. Single nucleotide polymorphisms (SNP) in the fibroblast growth factor receptor 2 (FGFR2) gene are substantially associated with postmenopausal breast cancer risk and could influence hormone therapy effects. Participants and METHODS: We interrogated eight SNPs in intron 2 of the FGFR2 gene for 2,166 invasive breast cancer cases from the Women's Health Initiative clinical trial and one-to-one matched controls to confirm an association with breast cancer risk. We used case-only analyses to examine the dependence of estrogen plus progestin and estrogen-alone odds ratios on SNP genotype. RESULTS: Seven FGFR2 SNPs, including six in a single linkage disequilibrium region, were found to associate strongly (P < 10(-7)) with breast cancer risk. SNP rs3750817 (minor allele T with frequency 0.39) had an estimated per-minor-allele odds ratio of 0.78, and was not in such strong linkage disequilibrium with the other SNPs. The genotype of this SNP related significantly (P < 0.05) to hormone therapy odds ratios. For estrogen plus progestin, the odds ratios (95% confidence intervals) at 0, 1, and 2 minor SNP alleles were 1.52 (1.14-2.02), 1.33 (1.01-1.75), and 0.69 (0.41-1.17), whereas the corresponding values for estrogen alone were 0.74 (0.51-1.09), 0.99 (0.68-1.44), and 0.34 (0.15-0.76). CONCLUSIONS: Postmenopausal women having TT genotype for SNP rs3750817 have a reduced breast cancer risk and seem to experience comparatively favorable effects of postmenopausal hormone therapy. (Cancer Epidemiol Biomarkers Prev 2009;18(11):3079-85). JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology SN - 1538-7755 TI - Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer. KW - breast KW - cancer KW - fgfr2 KW - polymorphism AU - Prentice, Ross AU - Huang, Ying AU - Hinds, David AU - Peters, Ulrike AU - Pettinger, Mary AU - Cox, David AU - Beilharz, Erica AU - Chlebowski, Rowan AU - Rossouw, Jacques AU - Caan, Bette AU - Ballinger, Dennis PY - 2009/10/27/ UR - http://dx.doi.org/10.1158/1055-9965.EPI-09-0611 ER -